Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role.
Enhancing the efficacy of cisplatin in ovarian cancer treatment - could arsenic have a role.
复制标题
DOI：
10.1186/1757-2215-2-2
复制
发表时间：
2009-01-14
影响因子：
4
通讯作者：
States JC
中科院分区：
文献类型：
--
作者：
Helm CW;States JC
卵巢癌每年影响全世界20多万妇女。大多数妇女直到疾病已经从卵巢转移才被诊断出来，结果预后不良。卵巢癌与略高于50%的总体5年生存率相关。一线治疗的支柱是细胞减灭术，然后是化疗。传统上，这一直是通过静脉途径，但有更多的兴趣在利用腹膜屏障的药物治疗优势的腹膜内化疗的输送。尽管三项比较静脉与腹腔化疗的大型随机临床试验显示，通过腹腔途径接受至少部分化疗的患者的结局有所改善。在过去的40年里，顺铂一直是治疗卵巢癌最有效的药物，卵巢癌女性的预后可以通过肿瘤对顺铂的反应来确定。那些在初始治疗时肿瘤先天性铂耐药的患者预后非常差。虽然大多数卵巢癌患者对一线铂类联合化疗有反应，但大多数患者会发展成对顺铂耐药的疾病，并最终死于疾病。提高顺铂的疗效可能对对抗这种疾病产生重大影响。亚砷酸盐是一种激动人心的药物，它不仅对卵巢癌细胞系具有固有的单药杀肿瘤活性，而且具有多种生物化学相互作用，可增强顺铂的细胞毒性，包括抑制脱氧核糖核酸（DNA）修复。体外研究表明，亚砷酸盐可能会增强顺铂在其他细胞类型中的活性。三氧化二砷已在临床上用于治疗急性早幼粒细胞白血病，证明其安全性。对卵巢癌的进一步研究是必要的，以确定其在这种疾病中的可能作用。
Ovarian cancer affects more than 200,000 women each year around the world. Most women are not diagnosed until the disease has already metastasized from the ovaries with a resultant poor prognosis. Ovarian cancer is associated with an overall 5 year survival of little more than 50%. The mainstay of front-line therapy is cytoreductive surgery followed by chemotherapy. Traditionally, this has been by the intravenous route only but there is more interest in the delivery of intraperitoneal chemotherapy utilizing the pharmaco-therapeutic advantage of the peritoneal barrier. Despite three large, randomized clinical trials comparing intravenous with intraperitoneal chemotherapy showing improved outcomes for those receiving at least part of their chemotherapy by the intraperitoneal route. Cisplatin has been the most active drug for the treatment of ovarian cancer for the last 4 decades and the prognosis for women with ovarian cancer can be defined by the tumor response to cisplatin. Those whose tumors are innately platinum-resistant at the time of initial treatment have a very poor prognosis. Although the majority of patients with ovarian cancer respond to front-line platinum combination chemotherapy the majority will develop disease that becomes resistant to cisplatin and will ultimately succumb to the disease. Improving the efficacy of cisplatin could have a major impact in the fight against this disease. Arsenite is an exciting agent that not only has inherent single-agent tumoricidal activity against ovarian cancer cell lines but also multiple biochemical interactions that may enhance the cytotoxicity of cisplatin including inhibition of deoxyribose nucleic acid (DNA) repair. In vitro studies suggest that arsenite may enhance the activity of cisplatin in other cell types. Arsenic trioxide is already used clinically to treat acute promyelocytic leukemia demonstrating its safety profile. Further research in ovarian cancer is warranted to define its possible role in this disease.
登录
查看更多内容
影响因子：
158.5
作者：
Alberts, DS;Liu, PY;Hoskins, WJ
通讯作者：
Hoskins, WJ
影响因子：
4.7
作者：
Eisenkop, SM;Spirtos, NM
通讯作者：
Spirtos, NM
影响因子：
4.7
作者：
Eisenkop, SM;Friedman, RL;Wang, HJ
通讯作者：
Wang, HJ
DOI：
10.1073/pnas.89.7.3070
发表时间：
1992-04-01
影响因子：
11.1
作者：
GODWIN, AK;MEISTER, A;ANDERSON, ME
通讯作者：
ANDERSON, ME
影响因子：
3
作者：
Du, YH;Ho, PC
通讯作者：
Ho, PC